comparemela.com

Latest Breaking News On - Deep len - Page 1 : comparemela.com

Icon PLC (ICLR) Q3 2021 Earnings Call Transcript

Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer

Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Central Care Cancer Center and Deep Lens Partner to Integrate AI-Matching Solution, VIPER™, Into Network, Expanding Clinical Research Program

Central Care Cancer Center and Deep Lens Partner to Integrate AI-Matching Solution, VIPER™, Into Network, Expanding Clinical Research Program
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

The CenterTX to deploy Deep Lens AI-based solution for clinical trials

The CenterTX to deploy Deep Lens’ AI-based solution for clinical trials 04 Jun 2021 (Last Updated June 4th, 2021 16:32) VIPER can identify qualified patients for clinical trials by integrating into The CenterTX’s molecular data feeds directly. Share Article VIPER will use cloud-based technology to facilitate and accelerate the clinical trial recruitment process. Credit: Michal Jarmoluk from Pixabay. The Center for Cancer and Blood Disorders (The CenterTX) in the US is set to deploy Deep Lens’ artificial intelligence (AI)-based clinical trial screening and enrolment solution VIPER. Using Cloud-based technology, VIPER will facilitate, triage, and accelerate the clinical trial recruitment process. Through its partnership with Deep Lens, The CenterTX will broaden its clinical trial offering by improving efficiencies related to recruitment and expanding the number of available trials for eligible subjects.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.